Research reading room
BRAF Fusions - IMPACT Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)
Summary
BRAF Fusions - IMPACT Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024) is a study catalogued by cBioPortal DataHub under the cancer-type code mixed. EvidenceHelix groups it with multiple or not classified from the title studies.
Study description
Targeted sequencing of 105 clinical cases via MSK-IMPACT to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is complemented by a parallel study using MSK-ARCHER sequencing (see related MSK-ARCHER (https://www.cbioportal.org/study/summary?id=braf_msk_archer_2024) study).
Text as published in the source's study metadata.
Citation & PubMed
Monica F et al. Clin Cancer Res 2024
Linked PubMed records: PMID 38922339
Source & licence
Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.
Source metadata
- Study identifier
- braf_msk_impact_2024
- Short name
- not given
- Source cancer-type code
- mixed
- Reference genome
- not given
- Source access groups
- not given
- Original study
- View on cBioPortal
- Metadata file
- meta_study.txt at e1b75cd25b
- Database licence
- ODC Open Database License (ODbL) 1.0
Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.
Citations
Monica F et al. Clin Cancer Res 2024
Citation counts are not part of the source metadata and are not shown.
Related studies
-
BRAF Fusions - ARCHER Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)
Targeted sequencing of 107 clinical cases via ARCHER to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is complement…
Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1 -
Cancer Therapy and Clonal Hematopoiesis (MSK, Blood Adv 2023)
Targeted sequencing of 47,532 patient samples with mixed tumor types and their matched normals to identify clonal hematopoiesis mutations using MSK-IMPACT.
Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1 -
Cancer Therapy and Clonal Hematopoiesis (MSK, Clin Cancer Res 2022)
Clonal hematopoiesis mutations identified in blood samples from patients whose tumor-blood pairs were analyzed using MSK-IMPACT.
Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1 -
Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)
Clonal hematopoiesis mutations identified in blood samples from 24,146 patients whose tumor-blood pairs were analyzed using MSK-IMPACT.
Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1 -
Cerebrospinal Fluid Circulating Tumor DNA (MSK, Acta Neuropathol Commun 2024)
Targeted sequencing of 1,007 cerebrospinal fluid circulating tumor DNA from patients with central nervous system tumors using MSK-IMPACT and their matched normals.
Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1 -
Mixed cfDNA (MSK, Nature Medicine 2019)
Targeted sequencing of 248 samples from 124 patients' cfDNA/WBC and tumor/normal pairs.
Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1 -
Mixed Tumors - MiMSI Cohort (MSK, Nat Commun 2024)
Targeted sequencing of 5,033 clinical cases and their matched normals via MSK-IMPACT, with pathologist-confirmed orthogonal MMR IHC data.
Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1 -
Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)
Targeted sequencing of Selpercatinib treated RET-driven solid cancers.
Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1